



Research Findings of F573 Published

Tokyo, March 16, 2011 – GNI Group Ltd, a leading biopharmaceutical company in Japan and China, is pleased to announce the publication of a research article regarding the use of F573 (formerly F1013) in the therapy of acute liver injury. This article has been published in the Chinese Pharmacological Bulletin (2012 Volume 28 (1): 136-139). The study was completed in the National Institute for Food and Drug Control at Beijing.

The ConA-induced acute liver injury model study involved 60 mice. F573 was given intravenously. Liver cell death and other liver functions were monitored. The conclusion was that F573 had a therapeutic effect on mice with acute liver injury. TNF- α level and cell apoptosis were both decreased. In previous unpublished studies, the same group of researchers also found that F573 effectively reduced mice mortality caused by acute liver injury. These animal studies provided important proof and direction for future human studies.

The most frequent cause of liver failure in China is hepatitis caused by HBV. Acute liver failure is represented by widespread liver cell death. Other than anti-viral therapy, there is no effective therapy directed against cell death. If F573 can be proved safe and efficacious in human, it will bring hope to millions of patients worldwide. In 2011, Shanghai Genomics has filed IND in China for clinical trials.

About GNI

Founded in 2001, GNI Group, Ltd. is a clinical-stage international drug development group with its headquarters in Tokyo, Japan, and research operations in Shanghai, China. In June 2005, GNI acquired Shanghai Genomics, which was also founded in 2001, and currently operates an integrated drug discovery and development platform in Shanghai. The combined strengths of GNI and Shanghai Genomics have resulted in research collaborations with major international pharmaceutical companies. For further information, please visit www.gnipharma.com and www.shanghai-genomics.com.

For further inquiries

Shinobu Tanaka Tel: +81 (03) -5326-3097
 Email: ir@gnipharma.com
Ying Luo Email: bd@shanghai-genomics.com

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to," "will," "intend to," "strive to" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. There is no guarantee that SFDA of China may approve the Company's NDA application. GNI does not undertake any obligation to update forward-looking statements.